Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions

DALLAS and BOSTON, Jan. 14, 2020 /PRNewswire-PRWeb/ -- Concerto HealthAI, the market leader for Real-World Data (RWD) and enterprise AI technology, announced today an agreement with Precision Health Informatics, a subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine to treat cancer patients. Precision Health Informatics will work with Concerto HealthAI to advance RWD solutions, research studies, and AI-enabled technologies – focusing on genomic and molecular characterization of patient disease to develop effective new therapies to treat some of the most challenging and devastating cancers.

Precision Health Informatics will leverage Concerto HealthAI's eurekaHealth 3.0 enterprise AI solution to advance precision medicine solutions for clinical research. Using AI models to enrich clinical data, Precision Health Informatics will more quickly derive insights from patient data to inform new study designs or identify eligible patients for clinical studies. Precision Health Informatics joins an expanding set of Concerto HealthAI's Real-World Evidence collaborators, such as theAmerican Society of Clinical Oncology's CancerLinQ® relationship announced in late 2017.

"Precision Health Informatics' model uses information from the molecular profile representing the genetics of the patient's disease combined with the clinical information specific to that patient to develop personalized medicine solutions that are integral to diagnosing cancer and offering physicians and patients effective treatment options," said Lori Brisbin, Vice President for Precision Health Informatics, "Concerto HealthAI's leadership in solutions for precision medicine will help us derive more meaningful insights from patient data, that in turn may help us connect patients with appropriate clinical trials."

"Using data from Texas Oncology's large patient base, Precision Health Informatics is at the forefront of precision medicine, innovative cancer testing and diagnostic approaches, such as Next Generation Sequencing – changing and improving the standard of care for patients. Ultimately, this is all about developing and connecting cancer patients to precise, effective treatment," said R. Steven Paulson, MD, President of Precision Health Informatics, and President and Chairman of Texas Oncology. "Concerto HealthAI's deep expertise in research-grade RWD solutions and AI technologies make it the ideal collaborator with Precision Health Informatics to help us more quickly develop medical innovations that benefit patients in our practice and elsewhere."

"At Concerto HealthAI, we seek clinical collaborators committed to advancing insights and new treatment strategies for patients with the highest unmet medical needs," said Jeff Elton, PhD, CEO of Concerto HealthAI. "Precision Health Informatics is making a deep commitment to enabling precision medicine, which we see as highly complementary to the work of our biomedical innovator partners."

This collaboration will advance novel research solutions, integrating deep clinical insights derived from electronic medical record data, particularly information about the molecular basis of disease derived from tissue or liquid samples. The value of these insights in helping connect patients to effective treatment options will be made available to Texas Oncology patients through its precision medicine program.

About Concerto HealthAI
Concerto HealthAI is a technology leader in Definitive Real-World Data (RWD) and AI solutions for Precision Oncology. Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent. Our focus is on revolutionizing clinical and outcomes research to accelerate the insights benefitting patient treatment. For more information, visit us at http://www.concertohealthai.com.

About Precision Health Informatics and Texas Oncology
Precision Health Informatics, a subsidiary of Texas Oncology, is a precision medicine solutions company that uses patients' genetic information for innovative testing, diagnostics, and treatment of cancer. Precision Health Informatics' solutions are based on data-driven insights from a vast, diverse patient base. Texas Oncology is an independent private practice with more than 460 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 90 FDA-approved therapies, about one-third of all cancer therapies approved to date. For more information, visit http://www.texasoncology.com.

MEDIA CONTACTS

Jen Toole
Concerto HealthAI
617.779.1828
[email protected]

Ed Bryson
Texas Oncology
512.592.8190
[email protected]

SOURCE Concerto HealthAI